Randomized trial evaluates ecopipam for Tourette syndrome, showing implications for therapy.
To evaluate the efficacy/safety of ecopipam, a selective dopamine D1 receptor antagonist, as a maintenance therapy in children/adolescents/adults with Tourette syndrome (TS).
No takes yet. Share an insight, caveat, or question.
Tomczak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: